Answer
Rifampicin reduces roflumilast’s total PDE4 inhibitory activity by about 60%, potentially reducing therapeutic efficacy, so roflumilast treatment is not recommended in patients receiving rifampicin, a strong cytochrome P450 enzyme inducer.
Sources for this answer
- DAXAS 500 micrograms film-coated tabletsAstraZeneca UK Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 16Document updated
Sources checked